Cannabidiol Inhibits RAD51 and Sensitizes Glioblastoma to Temozolomide in Multiple Orthotopic Tumor Models

Liliana Soroceanu¹, Eric Singer¹, Pratiksha Dighe¹, Max Sidorov¹, Chandani Limbad¹, Aida Rodriguez-Brotons¹, Peter Rix², Rinette W. L. Woo¹, Lawrence Dickinson³, Pierre-Yves Desprez¹, and Sean D. McAllister¹

1. California Pacific Medical Center Research Institute, San Francisco, CA 94107, USA
2. Launch Bioscience, San Diego, CA, 92130, USA
3. Eden Medical Center Sutter Research, Castro Valley, CA, 94546, USA

Correspondence to: Sean D. McAllister, California Pacific Medical Center Research Institute, 475 Brannan Street, Suite 130, San Francisco, CA 94107, USA. Telephone: (415) 600-5926; Email: mcallis@cpmcri.org

© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Funding: This study was funded by a sponsored research agreement from INSYS Therapeutics and the Research and Education Leadership Committee of the CPMC Foundation.

Conflict of Interest: Dr. McAllister and Dr, Soroceanu received funding in the past from INSYS therapeutics in the form of research service agreements, and Dr. McAllister and Dr. Desprez have patents for cannabinoid-based therapeutics; US20100204312A1 and US9254272B2. The sponsor played no role in the development of this manuscript. The additional authors have no potential competing interests to report.

Author Contributions: S.M. and L.S. wrote the manuscript and conceived experiments. P.R. assisted in experimental design and interpretation of the PK data. L.D. contributed primary GBM patient samples. S.M. and L.S. supervised the project, and assisted in experimental design and the in vivo experiments. P.Y.D. assisted in interpretation of the data and drafting the manuscript. E.S. and P.D. performed culture experiments, Western analysis and in vivo experiments. A.R. performed Western analysis. P.D., M.S., C.L. and R.W. performed in vivo experiments. All authors assisted in editing the manuscript and approved the final submitted manuscript.
Abstract

**Background.** Cannabidiol (CBD), a non-psychoactive cannabinoid with a low toxicity profile, has been shown to produce antitumor activity across cancers in part through selective production of reactive oxygen species (ROS) in tumor cells. The alkylating agent, temozolomide (TMZ), is standard of care for treatment of glioblastoma (GBM). It can trigger increased ROS to induce DNA damage. It has also been reported that down-regulating the expression of RAD51, an important DNA damage repair protein, leads to sensitization of glioblastoma to TMZ.

**Methods.** We determined the extent to which CBD enhanced the antitumor activity of TMZ in multiple orthotopic models of glioblastoma. In addition, we investigated the potential for CBD to enhance the antitumor activity of TMZ through production of ROS and modulation of DNA repair pathways.

**Results.** CBD enhanced the activity of TMZ in U87 MG and U251 GBM cell lines and in patient-derived primary GBM163 cells leading to stimulation of ROS, activation of the ROS sensor AMPK, and upregulation of the autophagy marker LC3A. CBD produced a sensitization of U87 and GBM163-derived intracranial (i.c.) tumors to TMZ and significantly increased survival of tumor-bearing mice. However, these effects were not observed in orthotopic models derived from GBM with intact methylguanine methyltransferase (MGMT).
expression. We further demonstrate that CBD inhibited RAD51 expression in MGMT-methylated models of GBM, providing a potential mechanism for tumor sensitization to TMZ by CBD.

**Conclusion.** These data support the potential therapeutic benefits of using CBD to enhance the antitumor activity of TMZ in GBM patients.

**Keywords**

Cannabidiol, patient-derived-xenograft, glioblastoma, sensitization to temozolomide

**Key points**

CBD produces enhancement of TMZ antitumor activity selectively in MGMT-methylated GBM leading to prolong survival. CBD inhibited RAD51 expression in MGMT-methylated GBM, providing a potential mechanism for tumor sensitization to TMZ by CBD.
Importance of Study

Development of effective treatment strategies for GBM is a high unmet need. This study demonstrates that CBD produces enhancement of TMZ antitumor activity selectively in MGMT-methylated GBM leading to prolong survival. This effect may in part be explained by CBD targeting of RAD51. Additional studies in GBM with the antitumor agent CBD, a brain penetrant cannabinoid with a low toxicity profile, are warranted.
Introduction

In the management of glioblastoma (GBM), surgery with postoperative radio- and chemotherapy, primarily with the alkylating agent temozolomide (TMZ), are the treatment of choice \(^1\). Additional tumor treatment modalities have also been FDA approved for the treatment of glioblastoma \(^2\). Despite these aggressive treatments, 90% of the patients die within 2 years \(^3\). Specifically, patients with an unmethylated O6-methylguanine–DNA methyltransferase (MGMT) promoter respond poorly to alkylating agents such as TMZ \(^3\). Thus, there is an urgent need for novel therapeutics strategies targeting GBM.

The cannabinoid (CB) \(\Delta^2\)-tetrahydrocannabinol (THC) activates two known CB receptors (CB\(_1\) and CB\(_2\)), which leads to the inhibition of cell proliferation and induction of apoptosis resulting in the reduction of tumor burden in vivo in multiple cancers, including GBM \(^4\)-\(^6\). These antitumor effects of CB\(_1\) and CB\(_2\) receptor agonists are thought to occur primarily through the endoplasmic reticulum (ER) stress-dependent up-regulation of autophagy-mediated cell death pathways (a caspase-independent form of programmed cell death) \(^6\)-\(^8\). However, the clinical utility of THC is limited by its psychoactive effects. There are more than 60 CBs in Cannabis sativa and a majority are not psychoactive \(^9\). Nonpsychoactive CBs found in reasonable abundance include cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC) \(^9\). CBD has negligible affinity for the cloned CB\(_1\) and CB\(_2\) receptors and does not directly target the classical endoCB system \(^10\)-\(^12\). We determined that in a screen of plant-based cannabinoids, that CBD was the most active at inhibiting cell viability/proliferation (viability) in cancer lines from different origins \(^13\). This effect has been shown to exhibit significantly lower potency in non-cancer cells \(^14\). The initial site CBD interacts with to produce antitumor activity is unknown. Multiple target sites have been implicated \(^15\), but the most unifying downstream mechanism in culture is the initial CBD-dependent selective production of reactive oxygen species (ROS) in tumor cells \(^16\).
This led us to hypothesize that non-psychoactive cannabinoids could be as effective as psychoactive CBs at inhibiting cancer progression and could reduce or replace the amount of psychoactive CBs used in the treatment of cancer. In support of this hypothesis, we previously reported that CBD can reduce the concentration of THC needed to inhibit GBM cell growth and induce apoptosis in culture \textsuperscript{17}. This result was confirmed by additional investigations \textit{in vivo} \textsuperscript{18} in subcutaneous xenograft tumor models, while our group has also demonstrated that CBD alone can inhibit human GBM progression in an intracranial xenograft mouse model \textsuperscript{19}.

As a result of the growing preclinical body of evidence of direct antitumor activity produced by THC and CBD, multiple clinical trials have evaluated the activity of cannabinoids in GBM. In a pilot study, intracranially administered THC was shown to be safe, in addition to inhibiting markers of tumor-cell proliferation \textsuperscript{20}. Sativex, a plant-based extract containing a 1:1 ratio of THC:CBD was also shown to prolong survival for GBM patients in a Phase IIb clinical trial, but the detailed results of the trial have not been publish \textsuperscript{21}. The direct antitumor activity produced by CBD has also recently been evaluated in clinical case studies across cancers, including GBM. Clinical responses were observed in a significant subset of patients supporting the need for future controlled clinical trials \textsuperscript{22,23}.

Taken together, these findings underscore the importance of understanding mechanisms of cannabinoid antitumor activity, which may further improve the activity of the cannabinoids and potentially lead to the development of more active second generation compounds.

In this study, we investigated the antitumor activity of cannabinoids alone and in combination with TMZ for targeting GBM progression in intracranial models using GBM cell lines and primary patient-derived GBM. In comparison to standard GBM cell lines, primary patient-derived GBM grown under glioma stem cell conditions more readily recapitulate the genotype, gene expression patterns (transcriptome), and \textit{in vivo} growth patterns of human GBM \textsuperscript{24}. Mechanistically, we focused on the antitumor properties of the non-psychoactive cannabinoid, CBD. We found CBD alone, in comparison to THC and the combination of CBD + THC, was as effective at sensitizing GBM
tumors to TMZ in multiple intracranial xenograft models. However, CBD did not sensitize TMZ-resistant GBM to TMZ in vivo. CBD-dependent stimulation of ROS led to inhibition of GBM cell viability in cell lines and primary patient-derived cultures. CBD enhanced the ability of TMZ to inhibit cell viability in part through production of ROS. CBD alone in combination with TMZ upregulated the expression of the ROS sensor AMP-activated protein kinase (AMPK), and the autophagy marker LC3A. CBD alone also inhibited RAD51 in TMZ-sensitive cell lines, but not in TMZ-insensitive cell lines. Importantly, CBD has a low toxicity profile in humans and is already being tested in clinical trials for GBM. Taken together, these data support CBD as a potential adjuvant therapy for targeting GBM.

Methods

Drugs

Cannabidiol (CBD) was obtained from INSYS Therapeutics, and Δ⁹-tetrahydrocannabinol (THC) was obtained from National Institutes of Health (NIH; Bethesda, MD) through the National Institute of Drug Abuse. All other chemicals and drugs were obtained through Selleckchem (Houston, TX).

Primary cell culture and in vivo passaging

Cultures were generated in-house from tissue samples obtained during surgical resection of patients diagnosed with GBM. As previously described, tumors were then subjected to enzymatic digest, mechanically dissociated and cultured as neurospheres as previously described. Tumor lines were maintained as subcutaneous flank xenografts in athymic nu/nu mice and processed as stated above.
**In vivo studies**

6-8 week old female athymic nu/nu mice with a weight range of 20-25 grams were obtained from Envigo (Indianapolis, IN). Human U87, U251, and T98 GBM cells were grown in RPMI media with 10% FBS and were harvested from dishes while in their exponential growth phase in culture with 0.1% trypsin/EDTA, and washed twice with serum-free RPMI media. Primary lines were grown as described above. For the intracranial model, tumors were generated in female athymic nu/nu mice by the intracranial injection of cells as detailed in the figure legends. Survival studies were carried out in accordance with the National Institutes of Health’s guidelines involving experimental neoplasia and our approved IACUC protocol. Animals in all groups were removed from the study when they demonstrated any single sign indicative of significant tumor burden development, including hunched back, sustained decreased general activity, or a significant decrease in weight. For drug treatment studies, cannabinoids were dissolved in a mixture of 2.5 % ethanol, 2.5 % Tween 80 and 95% saline, and TMZ was dissolved in 30% DMSO and 70% saline. Treatments were initiated based on the known progression of the tumors determined through pilot studies. For luciferase-labeled GBM tumors, mice were randomized based on imaging as previously described. When tumor cells were not luciferase-labeled, they were randomized based on their body weight. Animal health observations and removal from the study up first incidence of tumor burden development is described in Supplementary Information.

**Western blotting**

Western analysis was performed as previously described. Western blots were probed with the antibodies described in Supplementary Information. Anti-actin and anti-GAPDH were used as loading controls. The relative amounts of proteins were quantified using densitometry and the software program ImageJ (NIH).
Pharmacokinetic (PK) studies

To assess the PK of CBD, female BALBc mice were injected i.p with 15 mg/kg or 7 mg/kg of CBD. Blood samples were collected at 5, 15, 30 min and 1, 2, 5, 12, 24, and 48 hours after i.p. administration and analyzed as described in Supplementary Information.

Immunohistochemistry and immunofluorescence

Animal brains were harvested, fixed in 10% formalin and processed for immunohistochemistry and immunofluorescence as previously published by our group and as outlined in Supplementary Information.

Ethics Approval and Consent to Participate

Patient tumor tissue was collected under an IRB-approved research protocol in accordance with the Declaration of Helsinki. Informed consent was obtained from each patient in the study. All patient data was de-identified for the study. In vivo studies were carried out in accordance with the National Institutes of Health guidelines, Health Research Extension Act of 1985 and the Public Health Service Policy on Humane Care and Use of Laboratory Animals (Policy), Office of Laboratory Animal Welfare assurance, and an approved Institutional Animal Care and Use Committee (IACUC) protocol.

Data and statistical analyses

The IC50 values with corresponding 95% confidence limits were compared by the analysis of logged data using GraphPad Prism (La Jolla, CA). Significant differences were also determined using a one-
way ANOVA or the unpaired Student’s t-test, where suitable. Survival data was evaluated using Kaplan–Meir curves and a log-rank Mantel–Cox test. P-values <0.05 defined statistical significance. To test for synergism, the combination index (CI) was also calculated using Compusyn (Paramus, NJ) where CI <1, =1 and >1 indicates synergism, additive effect and antagonism, respectively, as previously described and as previously published by our group.

Results

CBD enhances the activity of TMZ in U87 and U251 GBM cells.

We determined whether CBD could enhance the activity of the first-line agent TMZ by evaluating the effects of the drugs alone or in combination (Figure 1A,B). U87 and U251 cells were treated for three days with a range of concentrations of either CBD, TMZ, or CBD + TMZ and the ability of the drugs to inhibit cell viability was assessed using the MTT assay. Using the calculated IC$_{50}$ values, various dose ratios of CBD and TMZ were combined in both U87 and U251 cells and viability was evaluated and a combination index (CI) throughout the dose ratios was calculated (Figure 1C). A CI value of <1, 1, and >1 indicates synergism, additivity, and antagonism, respectively. The combination of CBD and TMZ led primarily to additive inhibition of cell viability across multiple dose ratios in U87 and U251 cells.
CBD-dependent stimulation of ROS leads to inhibition of GBM cell viability.

CBD produces a sustained up-regulation of ROS in a concentration-dependent manner in U251 GBM cells leading to inhibition of cell viability (Figure 1D). This effect is not the result of interaction with CB₁ and CB₂ receptors, VR₁ receptors, or PPRγ, but was reversed by the ROS scavenger α-tocopherol (TOC) (Figure 1E). Inhibition of cell viability produced by the combination of CBD + TMZ was also blocked by TOC (Figure 1F). The ability of cannabinoids to sensitize GBM to TMZ in orthotopic models has not been evaluated, therefore, we next studied the effects of cannabinoids to sensitize human GBM to TMZ in vivo.

**Cannabinoids sensitize human U87-derived intracranial tumors to TMZ.**

We evaluated the ability of CBD alone or CBD + THC in a 1:1 ratio (CBD/THC) in combination with TMZ to inhibit tumor growth and extend survival in an intracranial (i.c.) model of GBM utilizing human U87 cells. In vivo imaging of luciferase-labeled U87 cells evaluated reduction in radiance (indirect measure of tumor size) in each treatment group (Figure 2A, B). CBD or CBD/THC did not inhibit GBM progression, however, these cannabinoids produced a sensitization of U87-derived tumors to TMZ leading to more effective inhibition of tumor progression and prolonged survival (Figure 2C). The mean survival for vehicle, CBD, CBD/THC, TMZ, CBD + TMZ, and CBD/THC + TMZ was 39, 43, 40, 46, 53, and 53 days, respectively (Figure 2C). Treatment with CBD + TMZ (P<0.043) or CBD/THC + TMZ (P<0.030) produced a significant improvement in survival in comparison to treatment with TMZ alone. Treatment with CBD + TMZ also produced full regression in 2 of the 11 tumors.
To determine whether the effect of CBD \textit{in vivo} was dose-dependent, we treated mice bearing U87-derived i.c. tumors with 3.75 mg/kg and 7.5 mg/kg of CBD alone or in combination with TMZ (Figure 2D and E). We observed full regression of a tumor in 1 of 11 mice in the CBD treatment group but overall there was no significant increase in survival in this group compared to control. We also observed full regression of tumor growth in 2 of 11 mice in the TMZ-treated group. In contrast to 15 mg/kg of CBD (Figure 2C), lower doses of cannabinoids did not enhance the antitumor activity of TMZ in an orthotopic mouse model of human glioblastoma (GBM). These data demonstrate that the ability of CBD to enhance the antitumor activity of TMZ is dose-dependent. PK parameters for CBD in plasma (Supplementary Table 1 and Supplementary Figure 1A,B) were compared between the 15 mg/kg (produced sensitization to TMZ) and 7.5 mg/kg (did not produce sensitization to TMZ) dosage levels to determine PK parameters that correlate with CBD-dependent production of TMZ sensitization. Plasma levels of CBD using LC/MS/MS analysis were determined and converted into time-concentration plots and PK parameters were calculated. To model the \textit{in vivo} experiments reported in this investigation, i.p administration was used to evaluate drug levels. Therefore, it was not possible to determine absolute bioavailability or the true elimination half-life because intravenous administration was not used. The dose of 15 mg/kg of CBD produced a $C_{\text{max}}$ of 3.3 $\mu$g/ml or 10.6 $\mu$M in plasma, with a calculated $\text{AUC}_{0-\infty}$ of 1.63 $\mu$g·hr/ml. The $C_{\text{max}}$ and $\text{AUC}_{0-\infty}$ were 2.5 and 2.7 time higher, respectively, in the 15 mg/kg compared to the 7.5 mg/kg CBD dosing group. The $T_{\text{max}}$ was similar between both dosing groups. Based on the antitumor studies, we chose to use a cannabinoid dose of 15 mg/kg for the remainder of the \textit{in vivo} studies.
Cannabinoids produce a sensitization of human U87-derived intracranial tumors to TMZ. GBM initiation, resistance to therapy, and recurrence has been shown to be driven by a subpopulation of tumor cells with stem-like characteristics, the glioma stem-like cells (GSC) \(^{31-33}\). In comparison to standard GBM cell lines, primary GBM grown under GSC conditions more readily recapitulated the genotype, gene expression patterns (transcriptome), and \textit{in vivo} growth patterns of human GBM \(^{24}\). We therefore evaluated whether CBD could enhance the antitumor activity of TMZ in a primary patient-derived xenograft (PDX) mouse model of GBM.

GBM163X cells were treated for three days with a range of concentrations of either CBD or TMZ, and the ability of the drugs to inhibit cell viability was assessed. Using the calculated IC\(_{50}\) values, various dose ratios of CBD and TMZ were combined and viability was evaluated and a combination index (CI) throughout the dose ratios was calculated (\textbf{Figure 3A}).

In GBM163X cells, the combination of CBD and TMZ led to slightly antagonist to additive inhibition of cell viability, as the fraction affected (reduction in cell viability) was increased. Inhibition of GBM163X cell viability produce by CBD or CBD + TMZ was blocked in the presence of TOC (\textbf{Figure 3B}). We next evaluated the ability of CBD alone or in combination with TMZ to inhibit tumor growth and prolong survival in an i.c. model of glioblastoma utilizing GBM163X. As shown in \textbf{Figure 3C}, the mean survival for vehicle, CBD, THC, CBD/THC, TMZ, CBD + TMZ, THC + TMZ, and CBD/THC + TMZ was 44, 43, 42, 42, 66, 78, 73, and 82 days, respectively. Treatment with TMZ alone prolonged survival (p<0.0001), however, treatment with CBD, THC, or CBD/THC alone did not. Treatment with CBD + TMZ (p<0.003), THC + TMZ (p<0.005), or CBD/THC + TMZ (p<0.0003) produced a significant improvement in survival in comparison to treatment with TMZ alone. While the combination of
CBD/THC + TMZ improved survival to the greatest extent, there was no significant difference between cannabinoids (CBD, THC, or CBD/THC) in the ability to sensitize GBM to TMZ. This is in agreement with what was observed in the U87-derived i.c. model. Both CBD alone and CBD + TMZ produced a sustained inhibition of tumor cell proliferation in vivo as evidenced by reduced Ki67 staining (Figure 3D and E). We next determined the antitumor activity of CBs alone or in combination with TMZ in GBM resistant to the antitumor activity of TMZ.

*CBD does not sensitize TMZ-resistant, MGMT unmethylated GBM to TMZ.*

We tested the activity of the combination of CBD + TMZ in the TMZ-resistant GBM T98 cell line and in the TMZ-resistant primary GBM 3832 cells (Figure 4). Unlike U87 and U251 cells, where MGMT levels are undetectable, 3832 and T98 cells express MGMT to a variable extent (Supplementary Figure 2). TMZ is an alkylating agent prodrug, delivering a methyl group to purine bases of DNA (O6-guanine; N7-guanine and N3-adenine). The primary cytotoxic lesion, O6-methylguanine (O6-MeG), can be removed by MGMT through direct DNA repair mechanism. Thus, in tumors expressing this protein, the antitumor activity of TMZ is reduced. In contrast to the effect of CBD + TMZ in U87 and U251 cells, the drug combination did not demonstrate additive or synergistic effects in T98 and 3832 cells (Figure 4A and B). We next evaluated the ability of CBD alone or in combination with TMZ to inhibit tumor growth and prolong survival in an i.c. model of primary glioblastoma utilizing 3832 cells. In vehicle-treated mice, this highly aggressive line produces tumors with a median survival of 35 days even at inoculations of 5,000 cells, with 50% of the populations of vehicle treated mice demonstrating symptoms of tumor burden between day 35 and 36. As shown in Figure 4C, the mean survival for vehicle, CBD, TMZ, and CBD + TMZ was 35.5, 39, 38, and 36 days, respectively. In comparison to GBM tumors with undetectable levels of MGMT, tumors derived from 3832 cells,
which express MGMT, demonstrated resistance to the antitumor activity of TMZ. Therefore, mice were administered a maximum tolerated dose of 75 mg/kg TMZ \textit{in vivo} (Figure 4C), and treatment with TMZ alone prolonged survival (P<0.02). CBD treatment increased animal survival (p<0.03), consistent with our previously published work \textsuperscript{26}; however, CBD in combination with TMZ was not significantly more effective than either drug alone (Figure 4C). Overall, the data demonstrate that CBD produces more robust enhancement of TMZ activity in GBM cells with lower levels of MGMT expression, which are more responsive to TMZ.

\textit{The combination of CBD + TMZ activates AMPK and upregulates the autophagy marker LC3-II.}

To further understand the mechanisms underlying the CBD-induced sensitization to TMZ, we next investigated the effects of CBD and TMZ on the AMPK and autophagy pathways. TMZ-sensitive U87 and GBM163X (Figure 5A and B) and TMZ-insensitive T98 and GBM3832 (Figure 5C and D) cells were treated with vehicle (control), CBD, TMZ or CBD + TMZ. The combination of CBD + TMZ was most efficient at activating the redox (ROS) sensor AMPK (via phosphorylation) in all the tumor cells tested, with varying degrees of AMPK activation produced by CBD and TMZ alone. Stimulation of AMPK leads to autophagy-mediated cell death \textsuperscript{35}. The conversion of the soluble form of LC3 (LC3-I) to the lipidated and autophagosome-associated form (LC3-II; lower band in the Western blot image) is considered one of the hallmarks of autophagy. A majority of the LC3-I to LC3-II conversion resulted from CBD treatment alone, with the exception of T98 cells where conversion was not observed. We next investigated additional pathways that may contribute to CBD-dependent sensitization of GBM to TMZ in TMZ-sensitive cells.
CBD inhibits the FOXM1-RAD51 pathway in TMZ-sensitive cell lines.

FOXM1 inhibition sensitizes resistant brain cancer cells to the first-line DNA damage agent TMZ by downregulating the expression of RAD51 gene, which encodes an important DNA damage repair protein. Our recently published work demonstrated that across multiple cancers CBD regulated a consistent set of transcription factors controlling tumor progression, including FOXM1. We therefore investigated whether CBD regulates the FOXM1-RAD51 pathway in this study. In TMZ-sensitive lines U87 and GBM163X (Figure 5A and B), CBD effectively inhibited RAD51 expression when cells were treated with CBD alone or in combination with TMZ. In contrast, CBD was ineffective at down-regulating RAD51 upon co-treatment with TMZ in TMZ-resistant cells (Figure 5C and D). The inhibitory effects of CBD on FOXM1 expression were only observed in the CBD alone treatment group in GBM163X, suggesting this target was not consistently modulated in either TMZ-sensitive or resistant glioblastoma.

In the presence of the ROS scavenger TOC, CBD was not effective at down-regulating RAD51 in GBM163X demonstrating dependence on production of ROS (Supplementary Figure 3A and B). RAD51 levels were also modulated by the combination of CBD and TMZ in vivo, following treatment of mice bearing GBM163X intracranial tumors with 15 mg/kg CBD and 2 mg/kg TMZ (Supplementary Figure 4).

Discussion

Glioblastomas are a heterogeneous group of high grade brain neoplasms that are notoriously resistant to conventional therapies. Therefore, the identification of non-toxic agents which can improve the efficacy of first-line therapies such as TMZ, possibly allowing for dose lowering, is urgently needed. Several other agents have been tested in combination
with TMZ, none of them had both the low toxicity profile and high brain blood barrier penetrance of CBD.

In this study, we determined whether CBD could enhance the activity of the first-line agent TMZ using multiple culture models of human GBM, including patient-derived tumors. The combination of CBD and TMZ led to primarily additive inhibition of cell viability in U87 and U251 cell culture models. There was some slight antagonism at lower dose ratios in primary GBM163X cells which may be a result of the increased resistance of primary GBM cells versus serum-derived cell lines. CBD produced a sustained up-regulation of ROS in a concentration-dependent manner in GBM cells leading to inhibition of cell viability. The inhibition of cell viability produced by CBD or the combination of CBD + TMZ was blocked by the ROS scavenger TOC.

We next evaluated the ability of cannabinoids alone or in combination with TMZ to inhibit tumor growth and extend survival i.c. models of MGMT-methylated GBM utilizing cell lines and patient-derived tumors. This study is the first to perform a direct comparison of the antitumor activity of CBD, THC, and CBD + THC alone and in combination with TMZ in orthotopic models. CBD, THC, nor CBD/THC alone inhibited GBM progression, however, these cannabinoids produced a similar sensitization of tumors to TMZ, leading to more effective inhibition of tumor progression and prolonged survival. This result is in agreement with previous studies targeting GBM with different ratios of CBD:THC + TMZ. In these investigations, treatments incorporating different ratios of CBD:THC alone targeting subcutaneous implanted GBM significantly inhibited tumor progression; all ratios tested, including treatments incorporating ratios with higher levels of CBD, for example 5:1 CBD:THC, were equally effective. Importantly, the antitumor activity of cannabinoids alone was not observed in intracranial (orthotopic) models, however, the ability of cannabinoids to sensitize GBM to TMZ was still observed. This difference is most likely the result of the difference in the tumor microenvironment. Indeed, using live-cell imaging, we have previously shown that after initial inhibition of tumor growth by CBD, intracranial GBM tumors
appear to resume a more rapid growth rate in spite of continuous CBD administration \(^{26}\), whereas treatment of GBM tumors implanted subcutaneously leads to a more stable inhibition \(^{(26,41)}\). Taken together, these data suggest that CBD alone, or in combination with lower concentrations of THC that do not produce unwanted psychoactivity, may be a preferred treatment regimen for development of clinical trials targeting GBM.

The ability of CBD to sensitize GBM to TMZ was dose-dependent in the U87 MG i.c. model. The PK parameters corresponding to the active dose of 15 mg/kg and the inactive dose of 7.5 mg/kg were compared allowing for an understanding of drug exposure needed to produce CBD-dependent sensitization of tumors to TMZ. CBD was rapidly absorbed following ip injection in mice, with maximal concentrations observed at the first sampling time point of 5 min post-dose. Systemic CBD exposure (plasma $C_{\text{max}}$ and AUC) was dose proportional between the 7.5 and 15 mg/kg dosage levels. Concentrations in the high dose decreased with a terminal half-life of 7.5 hr to a final concentration of 0.019 µg/mL by 12 hours post-dose.

In contrast to the effects of CBD + TMZ in MGMT-methylated GBM lines, the drug combination did not demonstrate additive or synergistic inhibitory effects in MGMT-unmethylated culture and in vivo models. These data demonstrate CBD produces enhancement of TMZ only in MGMT-methylated GBM, suggesting that MGMT-unmethylated GBM cells activate additional pathways leading to therapeutic resistance to the effect of CBD.

While subthreshold doses of TMZ are commonly used to study drug interactions in vivo \(^{41,42}\), it should be noted that using a higher dose of TMZ, approaching the maximum tolerated dose (MTD), in combination with CBD would have been a preferred treatment regimen to more closely model clinical care. There is the potential that cannabinoids would not further improve survival if the combination treatment included a significantly higher dose of TMZ. However, in TMZ-sensitive tumors, treatment with a higher dose of TMZ, approaching MTD, would result in a significant extension of survival for many months requiring long-term chronic treatment with cannabinoids which is not feasible due to animal
welfare concerns when considering i.p. injections of cannabinoids five days a week over many months.

The initial site CBD interacts with to produce antitumor activity is unknown, and the most unifying downstream mechanism in culture is the initial CBD-dependent production of ROS \textsuperscript{16}. Downstream of production of ROS, CBD has been shown to target multiple genes implicated in controlling tumor progression including TIMP1, PAI, ERK, AKT/mTOR, PUMA and CHOP \textsuperscript{43,44,45,46,47,48} as well as other pathways\textsuperscript{35}. We investigated the potential pathways modulated downstream of ROS that may explain why CBD is more effective at enhancing the activity of TMZ in MGMT-methylated vs MGMT-unmethylated GBM cells. The ROS sensor AMP-activated protein kinase (AMPK) is activated as a result of cellular stress, and through inhibition of the Akt-mTORC1 complex, lead ultimately to autophagy-mediated cell death \textsuperscript{35}. Both THC and CBD have been shown to up-regulate autophagy-mediated cell death markers in human GBM \textsuperscript{18,26}, and CB\textsubscript{1} and CB\textsubscript{2} receptor-induced apoptosis across cancers has been show to rely on stimulation of autophagy \textsuperscript{49}. CB\textsubscript{1} and CB\textsubscript{2} receptor agonists have been demonstrated to sensitize tumors to DNA damaging agents through mechanisms including AMPK autophagy-mediated cell death \textsuperscript{50,51}. In MGMT-methylated GBM cells the combination of CBD + TMZ was most efficient at activating AMPK, with varying degrees of AMPK activation produced by CBD and TMZ alone. In comparison to CBD, the combination of CBD + TMZ did not further improve the conversion of LC3-I to LC3-II, suggesting that a majority of the LC3-I to LC3-II conversion is the result of the treatment with CBD.

The Forkhead box protein M1 (FOXM1) transcription factor has been shown to promote tumorigenesis \textsuperscript{52}. FOXM1 inhibition sensitized resistant brain cancer cells to the first-line DNA damage agent TMZ by downregulating the expression of RAD51 gene, which encodes an important DNA damage repair protein \textsuperscript{36}. Since across cancers, CBD has been shown to inhibit the expression of specific transcription factors controlling tumor progression \textsuperscript{11,26}, including FOXM1 \textsuperscript{37}, we
investigated whether CBD modulates expression of FOXM1 and RAD51 in GBM. In MGMT-methylated lines, CBD effectively down-regulated RAD51 but not FOXM1, alone and in combination with TMZ. In contrast, CBD was ineffective at targeting RAD51 expression in MGMT-unmethylated GBM lines.

In this study, we demonstrate in multiple orthotopic models of MGMT-methylated GBM that cannabinoids can sensitize tumors to the chemotherapeutic agent TMZ. We also show for the first time that in MGMT-unmethylated GBM cells where MGMT expression is intact, CBD did not enhance the therapeutic effect of TMZ in culture or in orthotopic models. As clinical trial data for targeting GBM with cannabinoids becomes available, it would of interest to determine whether MGMT expression correlates with response to cannabinoids. CBD, a cannabinoid that does not produce psychoactive side-effects, was equally as effective as THC and the combination of CBD + THC at producing sensitization to TMZ in orthotopic mouse models of GBM. CBD and the combination of CBD + THC are already being tested in GBM in clinical trials or clinical case studies. The current investigation suggests that CBD alone, or combinations limiting the concentration of THC, may be a preferred treatment regimen that would limit psychotropic side effects. We also discovered that CBD effectively downregulates RAD51 in MGMT-methylated, but not in MGMT-unmethylated GBM cells. The targeting of RAD51 in MGMT-methylated GBM may in part explain why cannabinoids can sensitize tumors to TMZ in culture and in vivo in preclinical models of GBM.
Funding

This study was funded by a sponsored research agreement from INSYS Therapeutics and the Research and Education Leadership Committee of the CPMC Foundation.

Acknowledgments

We thank Dr. Jeremy Rich for sharing the primary-derived GBM 3832.
References

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-996.

2. Zhang H, Wang R, Yu Y, Liu J, Luo T, Fan F. Glioblastoma Treatment Modalities besides Surgery. J Cancer. 2019; 10(20):4793-4806.

3. Fernandes C, Costa A, Osorio L, et al. Current Standards of Care in Glioblastoma Therapy. In: De Vleeschouwer S, ed. Glioblastoma. Brisbane (AU)2017. Codon Publications; 2017 Sep 27. Chapter 11.

4. Blazquez C, Carracedo A, Salazar M, et al. Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology. 2008; 54(1):235-243.

5. Preet A, Ganju RK, Groopman JE. Delta(9)-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene. 2008 Jan 10;27(3):339-46.

6. Velasco G, Carracedo A, Blazquez C, et al. Cannabinoids and gliomas. Mol Neurobiol. 2007; 36(1):60-67.

7. Carracedo A, Lorente M, Egia A, et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell. 2006; 9(4):301-312.

8. Salazar M, Carracedo A, Salanueva IJ, et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest. 2009; 119(5):1359-1372.
9. McPartland JM, Russo EB. Cannabis and cannabis extract: greater than the sum of the parts? J. Cannabis Therapeut. 2001; 1:103-132.

10. Howlett AC. Cannabinoid inhibition of adenylate cyclase: relative activity of the constituents and metabolites of marijuana. Neuropharmacology. 1987; 26:507-512.

11. Devane WA, Dysarz F. A., Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988; 34:605-613.

12. Showalter VM, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. The Journal of Pharmacology and Experimental Therapeutics. 1996; 278:989-999.

13. McAlister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther. 2007; 6(11):2921-2927.

14. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006; 318(3):1375-1387.

15. Seltzer ES, Watters AK, MacKenzie D, Jr., Granat LM, Zhang D. Cannabidiol (CBD) as a Promising Anti-Cancer Drug. Cancers (Basel). 2020 Oct 30;12(11):3203.

16. Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as Potential Anticancer Drug. Br J Clin Pharmacol. 2013 Feb;75(2):303-12.

17. Marcu JP, Christian RT, Lau D, et al. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther. 2010; 9(1):180-189.
18. Torres S, Lorente M, Rodriguez-Fornes F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011; 10(1):90-103.

19. Soroceanu L, Murase R, Limbad C, et al. Id-1 is a Key Transcriptional Regulator of Glioblastoma Aggressiveness and a Novel Therapeutic Target. 2013 Mar 1;73(5):1559-69.

20. Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006; 95(2):197-203.

21. Hinz B, Ramer R. Anti-tumour actions of cannabinoids. Br J Pharmacol. 2019; 176(10):1384-1394.

22. Kenyon J, Liu W, Dalgleish A. Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol. Anticancer Res. 2018; 38(10):5831-5835.

23. Likar R, Koestenberger M, Stultschnig M, Nahler G. Concomitant Treatment of Malignant Brain Tumours With CBD - A Case Series and Review of the Literature. Anticancer Res. 2019; 39(10):5797-5801.

24. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006; 9(5):391-403.

25. Zusman E, Sidorov M, Ayala A, et al. Tissues Harvested Using an Automated Surgical Approach Confirm Molecular Heterogeneity of Glioblastoma and Enhance Specimen’s Translational Research Value. Front Oncol. 2019 Oct 23;9:1119.

26. Singer E, Judkins J, Salomonis N, et al. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis. 2015 Jan 15;6(1):e1601.
27. Murase R, Kawamura R, Singer E, et al. Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Br J Pharmacol. 2014; 171(19):4464-4477.

28. Soroceanu L, Matlaf L, Khan S, et al. Cytomegalovirus Immediate-Early Proteins Promote Stemness Properties in Glioblastoma. Cancer Res. 2015; 75(15):3065-3076.

29. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58(3):621-681.

30. Chou TC, Tan QH, Sirotnak FM. Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother Pharmacol. 1993; 31(4):259-264.

31. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-760.

32. Hjelmeland AB, Rich JN. The quest for self-identity: not all cancer stem cells are the same. Clin Cancer Res. 2012; 18(13):3495-3498.

33. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007; 67(19):8980-8984.

34. Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012; 5(1):102-114.

35. Cardaci S, Filomeni G, Cirilo MR. Redox implications of AMPK-mediated signal transduction beyond energetic clues. J Cell Sci. 2012; 125(Pt 9):2115-2125.

36. Zhang N, Wu X, Yang L, et al. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res. 2012; 18(21):5961-5971.
37. Desprez PY, Murase R, Limbad C, et al. Cannabidiol Treatment Results in a Common Gene Expression Response Across Aggressive Cancer Cells from Various Origins. Cannabis and Cannabinoid Research. 2021 Apr 15;6(2):148-155.

38. Bahadur S, Sahu AK, Baghel P, Saha S. Current promising treatment strategy for glioblastoma multiform: A review. Oncol Rev. 2019; 13(2):417.

39. Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res. 2017; 2(1):139-154.

40. Deiana S, Watanabe A, Yamasaki Y, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta(9)-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl). 2012; 219(3):859-873.

41. Lopez-Valero I, Saiz-Ladera C, Torres S, et al. Targeting Glioma Initiating Cells with a combined therapy of cannabinoids and temozolomide. Biochem Pharmacol. 2018; 157:266-274.

42. Lopez-Valero I, Torres S, Salazar-Roa M, et al. Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma. Biochem Pharmacol. 2018; 157:275-284.

43. Ramer R, Merkord J, Rohde H, Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol. 2010; 79(7):955-966.

44. Ramer R, Rohde A, Merkord J, Rohde H, Hinz B. Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharm Res. 2010; 27(10):2162-2174.
45. Morelli MB, Offidani M, Alesiani F, et al. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. Int J Cancer. 2014; 134(11):2534-2546.

46. Solinas M, Massi P, Cinquina V, et al. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PLoS One. 2013 Oct 21;8(10):e76918.

47. Soroceanu L, Murase R, Limbad C, et al. Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res. 2013; 73(5):1559-1569.

48. De Petrocellis L, Ligresti A, Schiano Moriello A, et al. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol. 2013; 168(1):79-102.

49. Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012. 2012 May 4;12(6):436-44.

50. Vara D, Salazar M, Olea-Herrero N, Guzman M, Velasco G, Diaz-Laviada I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ. 2011; 18(7):1099-1111.

51. Dando I, Donadelli M, Costanzo C, et al. Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. Cell Death Dis. 2013 Jun 13;4(6):e664.

52. Koo CY, Muir KW, Lam EW. FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta. 2012; 1819(1):28-37.

53. Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol. 2014; 171(3):636-645.
Figure Captions

Figure 1. CBD enhances the inhibitory effects of TMZ on GBM cell growth through up-regulation of ROS. A) U251 and B) U87 cells were treated for three days with vehicle, CBD, TMZ, or CBD + TMZ at specific combined dose ratios and cell viability (%) was calculated as absorbance in the treated cells/control cells x 100. C) These data were used to calculate combination index (CI) values as described previously by our group\textsuperscript{17,53} using Compusyn software. A CI value of <1, 1, and >1 indicates synergism (downward arrow), additivity (hashed line), and antagonism, respectively\textsuperscript{30}. D) U251 cells were treated for two days with vehicle or CBD (µM) and production of ROS was measured using 2′,7′Dichloro-dihydrofluorescein. E) U251 cells were treated for two days with 1.5 µM CBD (CBD) in the presence or absence of 200 µM γ-tocopherol (TOC), 1 µM CB1 receptor antagonist (SR141716A - SR1), 1 µM CB2 receptor antagonist (SR144528 - SR2), 1µM vanilloid receptor antagonist (capsazepine - CPZ), or 10 µM PPRg antagonist (GW 9662-GW). E) U251 cells were treated for three days with 1.5 µM CBD (CBD) + 200 µM TMZ in the presence or absence of 500 µM TOC. Data are the mean of 3 independent experiments; bars, ± SE. (*) and (‡) indicates statistically significant difference between control and CBD, respectively (p<0.05).

Figure 2. Cannabinoids (CBs) sensitize human GBM to TMZ in orthotopic mouse tumor models. Tumors were generated in female athymic nu/nu mice (n=11-12) by the intracranial (i.c.) injection of 0.3x10^6 U87 luciferase-labeled cells or U251 cells in 4µl of RPMI. Starting on day 9, CBs were administered i.p. 5 days a week until completion of the experiment. Starting on day 9, TMZ was administered i.p. 5 days a week for one week. Mice were treated with vehicle, 15mg/kg CBD, 15 mg/kg CBD/THC (1:1), 2 mg/kg TMZ, 15 mg/kg CBD + 15 mg/kg TMZ, and 15 mg/kg CBD/THC + 2 mg/kg TMZ and A) tumor progression, B) i.c. luciferase-based imaging of vehicle (top), TMZ at 2mg/kg (middle panel)
15mg/kg CBD + 2 mg/kg TMZ (bottom) at day 30, and C) survival were assessed. Mice bearing U87-derived i.c. tumors (n=11) were treated with 3.75 mg/kg and 7.5 mg/kg of CBD alone or in combination with TMZ and D) tumor progression and E) survival were assessed. Mice bearing U251-derived i.c. tumors (n=10-11) were treated with vehicle, 15 mg/kg CBD, 1.5 mg/kg TMZ, 15 mg/kg CBD + 1.5 mg/kg TMZ, and F) survival was assessed between vehicle and treated animals. Survival data was evaluated using Kaplan-Meir curves and the long-rank Mantel-Cox test. P < 0.05 defined statistically significantly differences.

Figure 3. Cannabinoids enhance the activity of TMZ in patient-derived orthotopic mouse tumor models. A) GBM163X cells were treated for three days with vehicle, CBD or TMZ alone at specific combined dose ratios (3μM CBD combined with 250 μM, 500μM, or 750μM of TMZ) and cell viability (%) was calculated as absorbance in the treated cells/control cells x 100. These data were used to calculate combination index (CI) values as described previously by our group using CompuSyn software. A CI value of <1, 1, and >1 indicates synergism (downward arrow), additivity (hashed line), and antagonism, respectively. B) GBM163X cells were treated for three days with vehicle (control), 2 μM CBD, 500 μM TMZ, or 2 μM CBD + 500 μM TMZ in the presence and absence of TOC and cell viability was evaluated. C) Tumors were generated in female athymic nu/nu mice by the intracranial (i.c.) injection of 0.3x10⁶ GBM163X cells in 4μl of RPMI. Starting day 21, CBs were administered i.p. 5 days a week until completion of the experiment. Starting on day 21, 1 mg/kg TMZ was administered i.p. 5 days a week for one week. Mice (n=8-12 for vehicle, TMZ, and drug combinations) were treated with vehicle, 15 mg/kg CBD, 15 mg/kg THC, 15 mg/kg CBD/THC (1:1), 1 mg/kg TMZ, 15 mg/kg CBD + 1 mg/kg TMZ (CBD + TMZ), 15 mg/kg THC + 1 mg/kg TMZ (THC + TMZ), and 15 mg/kg CBD/THC + 1 mg/kg TMZ (CBD/THC + TMZ) and C) survival was assessed. D) Representative microphotographs of H&E staining from GBM163-derived i.c. tumors treated as indicated (left and center panels). Right panels show Ki67 staining of the same tissue samples from mice treated with vehicle,
CBD, TMZ, and the combination of CBD + TMZ. Samples were collected at the time the animals succumbed to disease. Bar=200µm E) Bar graph shows quantification of Ki67 positive cells counting 6 fields from 2 different animals in each group (20X); the plotted numbers represent averages of Ki67 positive cells for 100 total human tumor cells/field. ** P<0.02 when compared to vehicle. Survival data was evaluated using Kaplan-Meir curves and the long-rank Mantel-Cox test. Data are the mean of 3 independent experiments; bars, ± SE. *, # indicates statistically significant from control and CBD, respectively (p<0.05).

Figure 4. CBD does not enhance the antitumor effects of TMZ in TMZ-resistant GBM.

A) T98 cells and B) 3832 primary cells where treated with vehicle (control), 1.5 µM CBD, 200 µM TMZ, or 1.5 µM CBD + 200 µM TMZ for three days and cell viability was evaluated. Data are the mean of 3 independent experiments; bars, ± SE. (*) indicates statistically significant interaction (p<0.05). C) Athymic nu/nu mice (n=10) were injected i.c. with 1x10^4 patient-derived GSC 3832 cells labeled with luciferase. Treatments started at day 9 following BLI confirmation of tumor presence (using bioluminescence measurements) and randomization of mice. Mice were treated with vehicle, CBD (15 mg/kg), TMZ (75mg/kg) or CBD (15 mg/kg) + TMZ (75mg/kg) and survival was assessed. Survival data were evaluated using Kaplan-Meir curves and the long-rank Mantel-Cox test.

Figure 5. CBD stimulates AMPK, upregulates LC3-II conversion, and inhibits FOXM1 and RAD51 expression in TMZ-sensitive GBM cell lines.

A) U87 were treated for three days with vehicle (control), 1.5 µM CBD, 200 µM TMZ, or 1.5 µM CBD + 200 µM TMZ and B) GBM163X were treated for three days with vehicle (control), 3 µM CBD, 500 µM TMZ, or 1.5 µM CBD + 500 µM TMZ. C, D) T98G and 3832 cells were treated for three days with vehicle (control), 1.5 µM CBD, 200 µM TMZ, or 1.5 µM CBD + 200 µM TMZ. The expression of pAMPK, tAMPK, LC3A, FOXM1, and RAD51 were
evaluated using Western analysis and Image J, respectively. Actin or GAPDH served as a loading control.
Figure 1
Figure 2

A

B

C

D

E

Figure 2
Figure 3

A

Combination Index

Synergetic Interaction

Fraction affected (Fa)

B

Viability (%)

Control

CBD 15 mg/kg

THC 15 mg/kg

CBD/THC 15 mg/kg

TMZ 1 mg/kg

CBD + TMZ

CBD/THC + TMZ

C

Survival (%)

Days

20

40

60

80

100

Vehicle

CBD 15 mg/kg

THC 15 mg/kg

CBD/THC 15 mg/kg

TMZ 1 mg/kg

CBD + TMZ

CBD/THC + TMZ

p < 0.0001

D

Vehicle

TMZ (1 mg/kg)

CBD (15 mg/kg)

CBD + TMZ

E

Ki67 positive cells/100

Vehicle

CBD 15 mg/kg

TMZ 1.5 mg/kg

CBD + TMZ

p < 0.0001
Figure 4
Figure 5